Kiniksa Pharmaceuticals International, plc $KNSA Stock Holdings Trimmed by American Century Companies Inc.

Key Points

• American Century Companies Inc. has significantly reduced its stake in Kiniksa Pharmaceuticals, selling 21,085 shares to hold 20,333 shares, a 50.9% decrease in ownership as reported in its latest SEC filing.
• Kiniksa Pharmaceuticals reported a Q2 earnings per share (EPS) of $0.23, exceeding analysts' expectations of $0.18 with a revenue of $156.80 million for the quarter.
• The stock had a price target increase from analysts, with Jefferies raising it to $54.00, while Wells Fargo set it at $42.00, indicating a strong interest in the company’s growth potential.

American Century Companies Inc. lowered its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 50.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,333 shares of the company's stock after selling 21,085 shares during the quarter. American Century Companies Inc.'s holdings in Kiniksa Pharmaceuticals International were worth $452,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KNSA. GAMMA Investing LLC boosted its holdings in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the last quarter. US Bancorp DE acquired a new position in Kiniksa Pharmaceuticals International in the first quarter valued at $33,000. Asset Management One Co. Ltd. acquired a new position in Kiniksa Pharmaceuticals International in the first quarter valued at $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals International in the first quarter valued at $42,000. Finally, Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at $61,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $35.66, for a total transaction of $477,451.74. Following the sale, the chief operating officer directly owned 44,452 shares of the company's stock, valued at approximately $1,585,158.32. The trade was a 23.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ross Moat sold 3,523 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $35.31, for a total value of $124,397.13. Following the sale, the insider directly owned 9,415 shares in the company, valued at approximately $332,443.65. The trade was a 27.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 562,271 shares of company stock valued at $18,716,309. Company insiders own 53.48% of the company's stock.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of research analyst reports. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday. Finally, Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA traded up $0.78 during midday trading on Thursday, reaching $37.01. 403,194 shares of the company's stock were exchanged, compared to its average volume of 415,069. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $37.25. The stock has a market capitalization of $2.74 billion, a PE ratio of 925.48 and a beta of 0.20. The business's fifty day moving average price is $31.68 and its two-hundred day moving average price is $26.96.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.